Beta Bionics, Inc.

In the United States, customer orders for the iLet are typically fulfilled by billing third-party payors on behalf of customers or through our network of distributors that bill payors directly. Historically, most insulin pumps, including the iLet, are eligible for insurance reimbursement for replacement approximately once every four years, though certain health plans may extend this period or impose additional restrictions. We have entered into contracts with national and regional third-party payors to establish reimbursement for the iLet and related supplies, and we continue to expand the number of payors that provide direct coverage under both the DME and PBP channels. If we are not contracted with a prospective customer’s payor, and in-network status cannot otherwise be obtained, we seek to fulfill orders through alternate distribution partners where possible. A payor’s decision to cover our product does not guarantee an adequate reimbursement rate, and coverage policies or reimbursement levels may change over time. Even if favorable coverage and reimbursement are achieved, future changes in payor policies or healthcare reform measures could adversely affect reimbursement terms or patient access.